Aroa Biosurgery Ltd (arx) Logo

Aroa Biosurgery Ltd (ARX)

___:___ · Healthcare

ARX Chart


ARX's Principal Activity is the the development, manufacture and distribution of products to improve the healing in complex wounds and soft tissue reconstruction.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -27.49%
vs ASX 200 (1yr) -30.75%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 633 of 2,413
Sector Rank 40 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies RAC / PSQ / PAR
EPS $0.034
DPS $0.00
Book Value Per Share $0.18

Broker Consensus

ARX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Aroa Biosurgery Limited (ARX) is a soft tissue regeneration company focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. It participates in the wound care and surgical reconstruction markets. Its products currently for sale in the key US market target chronic wounds and soft tissue reconstruction including, hernia, breast reconstruction and trauma/limb salvage/ tumour surgery.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Mangere Auckland New Zealand 2022
Registry BoardRoom
Auditor BDO Auckland
Date Listed 24 Jul 2020

Upcoming Calendar (Forecasted)

Date Event
24/05/2022 Report (Prelim)
21/06/2022 Report (Annual)
24/11/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Tracy Weimar Joint Company Secretary Jul 2020
Mr John Flower Diddams Non-Executive Director Nov 2019

Mr John Flower Diddams

Non-Executive Director

Mr Diddams has over forty years' experience as a CFO, CEO and director of both private and publicly listed companies. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations' law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in a number of industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors. John is currently a non-executive director of New Zealand based Volpara Health Technologies Limited (ASX:VHT) and Surf Lakes Holdings Limited. He is also Chair of the Risk Committee of the company.

Mr Steven (Steve) Barnard Engle Non-Executive Director Apr 2015

Mr Steven (Steve) Barnard Engle

Non-Executive Director

Mr Engle has over 20 years of executive leadership experience with public biotech companies developing products in metabolic, autoimmune, oncologic and infectious disease areas. He is the Chief Executive Officer of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Before joining CohBar, Steven served as CEO of Averigon Consulting, an advisory firm to the life science industry, supporting companies through product partnering, regulatory planning, investor relations and executive management. Previously, he was Chairman and CEO of XOMA Corporation, a leader in the development of therapeutic antibodies and antibody technologies. Prior to XOMA, Steven served as Chairman and CEO of La Jolla Pharmaceutical Company. Earlier, he served as Vice President of Marketing for Cygnus, a drug delivery systems company, where he helped to gain FDA approval and to launch Nicotrol for smoking cessation. Steven is the non-executive Chairman of the Board of Prescient Therapeutics Ltd., an ASX listed clinical stage oncology company, and a director of the board of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM, and was a Member of the board of the Lupus Foundation of America.

Mr John Richard Pinion II Non-Executive Director Feb 2015

Mr John Richard Pinion II

Non-Executive Director

Mr Pinion has over 26 years of experience in biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical Development and QC. In the ten years prior to joining Ultragenyx, John has held roles of increasing responsibility at Genentech (subsequently Roche post Genentech acquisition), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland. Previous to Genentech, John spent 17 years in operational and senior leadership roles in Baxter International's Renal, Bioscience, Parenterals and Device divisions. He is also member of the Risk Committee of the company.

Mr James (Jim) Neil McLean Non-Executive Chairman,Non-Executive Director Aug 2011

Mr James (Jim) Neil McLean

Non-Executive Chairman,Non-Executive Director

Mr McLean has gained 25 years experience serving as either Chair, Director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to Aroa, current appointments include Chair of Prevar Limited, R J Hill Laboratories Limited and Information Tools Limited. He was Chair of the New Zealand Institute of Plant & Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as deputy Chair. Jim was an executive and director of Genesis Research & Development Corporation Limited during its early stages through public listing. Before focusing in science and technology businesses, Jim held management positions with an international manufacturing business and spent thirteen years as a partner at chartered accountants, EY. His time at EY was focused on business strategy and included two years' secondment to EY's Washington DC office. He is a member of the Risk Committee.

Mr Philip John McCaw Non-Executive Director Mar 2008

Mr Philip John McCaw

Non-Executive Director

Mr McCaw is the Founding Partner of Movac, one of New Zealand's Venture Capital funds. Phil has over 20-years experience investing into New Zealand technology companies and helping to guide their growth. Phil was an early investor in Trade Me, New Zealand's on-line trading community, which was sold to Fairfax in 2006. He was also an early investor into PowerByProxi, a wireless power technology spin-out from Auckland University, which was sold to Apple in 2018. Outside of Movac, Phil remains an angel investor and maintains a personal angel investment portfolio. He is a advocate for the development of the entrepreneurial and early-stage investment eco-system in New Zealand and was the past Chair of the Angel Association of New Zealand; a founding investor in the Lightning Lab technology accelerator; and a founding investor in the Kiwi Landing Pad in San Francisco. Prior to starting Movac Phil spent 10-years with Deloitte Consulting working in New Zealand and the USA.

Mr Brian Roderick Ward Chief Executive Officer,Managing Director Sep 2007

Mr Brian Roderick Ward

Chief Executive Officer,Managing Director

Mr Ward has held senior corporate roles in life sciences and health care companies over the last 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on a number of government and industry expert panels.

Mr James Blair Agnew Chief Financial Officer,Joint Company Secretary N/A

Director Transactions

ARX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
12/04/22 James (Jim) McLean Buy +102,400 $0.75 $76,800 Exercise of options
12/04/22 James (Jim) McLean Exercise 102,400 $0.75 $76,800 Exercise of options
12/04/22 Philip McCaw Buy +81,925 $0.75 $61,443 Exercise of options
12/04/22 Philip McCaw Exercise 81,925 $0.75 $61,443 Exercise of options
25/03/22 John Diddams Buy +165,000 $0.107 $17,732 Exercise of options
25/03/22 John Diddams Exercise 165,000 $0.107 $17,732 Exercise of options
19/08/21 James (Jim) McLean Buy +102,400 $0.75 $76,800 Exercise of options
19/08/21 James (Jim) McLean Exercise 102,400 $0.75 $76,800 Exercise of options
06/08/21 Philip McCaw Transfer 2,864,879 $1.151 $3,298,621 Off-market transfer
11/06/21 Philip McCaw Buy +81,925 $0.75 $61,443 Exercise of options
11/06/21 Philip McCaw Exercise 81,925 $0.75 $61,443 Exercise of options
22/02/21 John Diddams Sell +200,000 $1.193 ($238,680) On-market trade
09/12/20 John Diddams Buy +165,000 $0.107 $17,737 Exercise of options
09/12/20 John Diddams Exercise 165,000 $0.107 $17,737 Exercise of options

Director Interests

The current holdings of ARX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
James (Jim) McLean 12/04/2022 2,777,108 N/A 102,400 N/A
Philip McCaw 12/04/2022 N/A 19,597,251 81,925 N/A
John Diddams 25/03/2022 N/A 977,550 165,000 N/A
Brian Ward 31/03/2021 N/A N/A 3,132,525 N/A
John Pinion II 31/03/2021 N/A N/A 879,000 N/A
Steven (Steve) Engle 31/03/2021 N/A N/A 879,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Jun 10, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Mark Ritcher (Ritcher Investments A/C) 200,890,889 1.37%
Mr Brian Ward & Mrs Tracey Ward (Arawai No 2 A/C) 33,125,800 11.02%
Movac Fund 3 Lp 18,679,050 6.21%
Citicorp Nominees Pty Limited 17,856,411 5.94%
Phil Mccaw (Mcsyth Capital Investment A/C) 16,722,425 5.56%
National Nominees Limited 16,075,659 5.35%
J P Morgan Nominees Australia Pty Limited 13,774,374 4.58%
Richard Abbott (Jester 002 Investment A/C) 11,579,775 3.85%
Hsbc Custody Nominees (Australia) Limited 8,293,333 2.76%
Washington H Soul Pattinson And Company Limited 7,499,800 2.49%
Aspire Nz Seed Fund Ltd 7,491,000 2.49%
Sparkbox Investments Ltd 7,312,050 2.43%
K One W One (No 3) Ltd 5,882,550 1.96%
Bnp Paribas Nominees Pty Ltd (Agency Lending Drp A/C) 5,051,704 1.68%
Bnp Paribas Noms Pty Ltd (Drp) 4,835,542 1.61%
Bnp Paribas Noms Pty Ltd (Drp) I 4,819,950 1.60%
Sharon Bryant (Ot Investment A/C) 4,815,198 1.60%
Mesynthes Nominees Ltd20 4,580,250 1.52%
Custodial Services Limited (Beneficiaries Holding A/C) 4,120,200 1.37%
Nancy Yopp 3,913,842 1.30%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 970 1,380 603 755 135 3,843

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
J P Morgan Nominees Australia Pty Limited 09/08/2021 24,401,862 7.15
National Nominees Limited 09/08/2021 22,112,806 6.48
Brian Ward 09/08/2021 33,125,800 9.70
Citicorp Nominees Pty Limited 09/08/2021 27,365,874 8.02
Phil McCaw 09/08/2021 19,669,229 5.76

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
09-08-21 Citicorp Nominees Pty Limited 27,365,874 -- 8.02
09-08-21 J P Morgan Nominees Australia Pty Limited 24,401,862 -- 7.15
09-08-21 National Nominees Limited 22,112,806 -- 6.48
09-08-21 Brian Ward 33,125,800 -- 9.70
09-08-21 Phil McCaw 19,669,229 -- 5.76

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
30-08-21 Movac Limited 18,679,050 6.21 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $1.07 30 June
2018 $0.30 29 June
2017 $0.515 28 June
2016 $0.45 28 June
2015 $0.001 30 June
2014 $0.003 30 June
ARX Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.